Efficacy of fluorouracil combined with paclitaxel and oxaliplatin for the treatment of advanced gastric signet ring cell carcinoma

Table 1 Comparison of clinical efficacy between the two patient groups

Treatment prescription	Sample	PR	SD	PD	ORR (%)	DCR (%)
Control group	42	8	20	14	19	66.7
Treatment group	43	14	20	9	32.5	79.1

DCR: Disease control rate; ORR: Objective response rate; PD: Progressive disease; PR: Partial remission; SD: Stable disease.

Table 2 Analysis of the relationship between serum index expression levels and treatment efficacy before and after chemotherapy (mean ± SD)

Detect items	Patients with PR (n = 22)		Patients with SD (n = 40)		Patients with PD (n = 23)		P value
	Before chemotherapy	After chemotherapy	Before chemotherapy	After chemotherapy	Before chemotherapy	After chemotherapy
CEA (ng/mL)	28.5 ± 27.8	22.6 ± 21.6	24.8 ± 25.7	23.4 ± 22.5	32.8 ± 31.8	44.6 ± 34.8	< 0.01
CA19-9 (ng/mL)	145 ± 117	116 ± 91	159 ± 127	164 ± 136	166 ± 115	186 ± 145	< 0.01
Serum albumin (g/L)	267 ± 155	278 ± 193	409 ± 267	405 ± 260	470 ± 258	413 ± 256	< 0.01
Serum total protein (g/L)	569 ± 385	509 ± 314	548 ± 256	526 ± 215	587 ± 258	596 ± 274	> 0.05

CA19-9: Carbohydrate antigen 19-9; CEA: Carcinoembryonic antigen; PD: Progressive disease; PR: Partial remission; SD: Stable disease.

Table 3 Occurrence of adverse drug reactions in the two groups of patients, n (%)

Treatment options	Nausea and vomiting	White blood cell decrease	Diarrhea	Peripheral sensation adverse reactions	Bone marrow suppression
Control group, n = 42	4 (9.5)	3 (7.14)	1 (2.38)	2 (4.76)	1 (2.38)
Treatment group, n = 43	5 (11.62)	2 (4.65)	2 (4.65)	3 (6.97)	1 (2.32)

Table 4 Clinical characteristics of 85 patients with advanced gastric signet ring cell carcinoma, n (%)

Characteristic	Value
Sex
Women	50 (58.8)
Men	35 (41.2)
Age (year)
Median	69
Range	65-78
ECOG
0	48 (56.5)
1	28 (32.9)
2	9 (10.6)
Primary tumor site
Esophagogastric junction	28 (32.9)
Gastric body/fundus	23 (27.1)
Gastric antrum	19 (22.4)
Leather stomach	15 (17.6)
Organs involved
Lymph nodes	51 (60.0)
Liver	31 (36.4)
Lung	9 (10.6)
Peritoneum	30 (35.3)
Other	10 (11.8)
Number of organs involved
1	23 (27.1)
2	33 (38.8)
> 2	29 (34.1)

ECOG: Eastern Cooperative Oncology Group.

Table 5 Efficacy data for 83 patients with advanced gastric signet ring cell carcinoma, n (%)

Parameter	Value
CR	11 (13.3)
PR	29 (34.9)
SD	34 (41.0)
PD	9 (10.8)
ORR	40 (48.1)
DCR	74 (89.1)

CR: Complete disappearance; DCR: Disease control rate; ORR: Objective response rate; PD: Progressive disease; PR: Partial remission; SD: Stable disease.

Table 6 Incidence of adverse events in patients with advanced gastric signet ring cell carcinoma after chemotherapy

Toxicity (NCI-CTCAE v 3.0)	Grade I	Grade II	Grade III	Grade IV	Grade I/II (%)	Grade III/IV (%)
Leukopenia	34	17	14	4	60.0	21.2
Neutropenia	20	13	15	4	38.8	22.4
Anemia	28	9	6	0	43.5	7.1
Thrombocytopenia	13	5	6	1	21.2	8.2
Nausea/vomiting	14	5	0	0	22.4	0
Diarrhea	20	4	0	0	28.2	0
Oral mucositis	5	3	5	0	9.4	5.9
Hepatic injury	29	18	4	0	55.3	4.7
Peripheral neurotoxicity	35	18	9	0	62.4	10.6
Anaphylaxis	0	0	0	0	0	0

NCI-CTCAE v3.0: National Cancer Institute Common Terminology Criteria for Adverse Events version 3.0.